RESEARCH ARTICLE

Mycobacterium tuberculosis IMPDH in Complexes with Substrates, Products and Antitubercular Compounds

Magdalena Makowska-Grzyska1, Youngchang Kim1,2, Suresh Kumar Gorla3, Yang Wei3, Kavitha Mandapati3, Minjia Zhang3, Natalia Maltseva1, Gyan Modi3, Helena I. Boshoff4, Minyi Gu1, Courtney Aldrich5, Gregory D. Cuny6,7, Lizbeth Hedstrom3,7*, Andrzej Joachimiak1,2*

1 Center for Structural Genomics of Infectious Diseases, University of Chicago, Chicago, IL, United States of America, 2 Structural Biology Center, Biosciences, Argonne National Laboratory, 9700 S Cass Ave. Argonne, IL, United States of America, 3 Department of Biology, Brandeis University, 415 South St. Waltham, MA, United States of America, 4 Tuberculosis Research Section, National Institute of Allergy and Infectious Diseases, Bethesda, MD, United States of America, 5 Center for Drug Design, Academic Health Center, University of Minnesota, 516 Delaware St. SE, Minneapolis, MN, United States of America, 6 Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, 549A Science and Research Building 2, Houston, TX, United States of America, 7 Department of Chemistry, Brandeis University, 415 South St. Waltham, MA, United States of America

* hedstrom@brandeis.edu (LH); andrzejj@anl.gov (AJ)

Abstract

Tuberculosis (TB) remains a worldwide problem and the need for new drugs is increasingly more urgent with the emergence of multidrug- and extensively-drug resistant TB. Inosine 5'-monophosphate dehydrogenase 2 (IMPDH2) from Mycobacterium tuberculosis (Mtb) is an attractive drug target. The enzyme catalyzes the conversion of inosine 5'-monophosphate into xanthosine 5'-monophosphate with the concomitant reduction of NAD+ to NADH. This reaction controls flux into the guanine nucleotide pool. We report seventeen selective IMPDH inhibitors with antitubercular activity. The crystal structures of a deletion mutant of Mtb IMPDH2 in the apo form and in complex with the product XMP and substrate NAD+ are determined. We also report the structures of complexes with IMP and three structurally distinct inhibitors, including two with antitubercular activity. These structures will greatly facilitate the development of Mtb IMPDH2-targeted antibiotics.

Introduction

Tuberculosis (TB) is a pandemic contagious infectious disease affecting nearly two billion people worldwide, with 5.7 million new cases reported in 2013 according to the World Health Organization [1]. The currently approved standard first-line treatment is long and requires combination therapy consisting of several antibiotics [2]. Mycobacterium tuberculosis (Mtb), the causative agent of most TB cases is a slow growing, remarkably successful pathogen capable of switching between different physiological states and adapting to disparate host environments...
The authors have declared that no competing interests exist.

M. tuberculosis IMP Dehydrogenase Inhibitors

The Mtb pathogen can persist in a quiescent state and survive for decades as a latent infection [3,4]. The increased prevalence of multidrug resistant (MDR) and extensively drug resistant (XDR) strains of Mtb, for which treatment options are very limited, demands the development of more effective antitubercular agents, ideally with novel mechanisms of action [6,7].

The design of antimetabolites that inhibit biosynthesis of essential metabolites within a cell is a classic approach for discovery of new antibiotics and chemotherapeutic agents. Indeed, one of the first reported TB drugs, para-aminosalicylic acid, was recently shown to disrupt folate biosynthesis [8], while the newest TB drug, bedaquiline exerts its activity through inhibition of ATP synthesis [9]. Inosine 5’-monophosphate dehydrogenase (IMPDH) lies at a key intersection of the purine biosynthesis pathway and represents an extremely attractive target since it controls flux of the guanine nucleotide pool. In many pathogens, guanine nucleotide levels are IMPDH-dependent and thus inhibition of IMPDH is a viable strategy for design of new chemotherapeutic agents [10]. The purine nucleotide biosynthetic pathway of Mtb, in common with other bacteria, contains three different enzymes from that of humans [11,12]: (1) Mtb contains both the folate dependent N1-(5-phospho-D-ribosyl)glycinamide (GAR) transformylase (PurN) and the formate/ATP utilizing formyl- N1-(5-phospho-D-ribosyl)glycinamide (FGAR) synthetase (PurT), whereas humans only contain GAR transformylase. (2) Humans use a type I 2-(formamido)-N1-(5-phospho-β-D-ribosyl)acetamidine (FAGM) synthetase composed only of PurL. Bacteria typically contain a type II FGM synthetase, which is a complex of PurLQS. Orthologs for both PurL and PurQ have been identified in Mtb, as has a candidate PurS, which suggests that Mtb also utilizes the type II enzyme [11]. (3) Whereas humans convert 5-amino-1-(5-phospho-D-ribosyl)imidazole (AIR) directly to 5-amino-1-(5-phospho-β-D-ribosyl)imidazole-4-carboxylate (C AIR) via a class II AIR carboxylase (PurE class II), Mtb uses N5-carboxyaminimidazole ribonucleotide (NCAIR) synthetase (PurK) to first convert AIR to NCAIR, then a class I AIR carboxylase converts NCAIR to CAIR. The remaining steps are common to both humans and Mtb. IMPDH catalyzes the NAD⁺-dependent conversion of inosine 5’-monophosphate (IMP) to xanthosine 5’-monophosphate (XMP), the first of the two step biosynthesis of guanosine 5’-monophosphate (GMP). GMP synthetase catalyzes the conversion of XMP to GMP in a reaction that also hydrolyzes glutamine to glutamate and ATP to AMP and pyrophosphate.

The Mtb H37Rv genome contains three genes with sequence similarity to bacterial IMPDH (guaB1, guaB2, and guaB3); the functions of guaB1 and guaB3 are poorly understood and only guaB2 was shown to encode an active IMPDH [13],[14] (S1 Fig [54, 55]). Consistent with this finding, the guaB2 gene is essential and cannot be rescued by the other orthologs [15]. The IMPDH activity of the guaB2 gene product, MtbIMPDH2, has been confirmed [14,16] and small molecule inhibitors have also been described [14,16,17].

The enzymatic mechanism of IMPDH has been extensively studied and consists two steps, a dehydrogenase and a hydrolase reaction (Fig 1A) [10,18]. Upon binding of IMP and NAD⁺ cofactor, a thioimide enzyme-substrate adduct, E-XMP⁺, is formed via a covalent bond to the catalytic C341 (MtbIMPDH2 numbering) with concurrent production of NADH. Hydride transfer occurs to the pro-S position with the cofactor in the anti-conformation (Fig 1B). The cofactor is released and an active site mobile flap moves into the NAD⁺ site and facilitates E-XMP⁺ hydrolysis with a conserved R443 acting as a general base. Thus, the enzyme has two distinct conformations, an open form for the dehydrogenase reaction and a closed form for E-XMP⁺ hydrolysis. IMPDH has multiple active site states (apoE, E•IMP, E•IMP•NAD⁺, E-XMP⁺•NADH adduct) that can be targeted for inhibitor design, and both the IMP/XMP and cofactor binding sites have been exploited for that purpose [10,18,19].

Human and bacterial IMPDHs differ in their affinity toward the NAD⁺ cofactor. While the nicotinamide portion of NAD⁺ binds similarly in human and Vibrio cholerae IMPDHs to
preserve the interaction with IMP for hydride transfer, the interactions of the adenosine moiety vary dramatically. In the human type II enzyme (hIMPDH2), the adenine ring π/π stacks between a pair of aromatic residues within the same monomer as the IMP binding site (H253 and F282 in hIMPDH2; referred to as the AE-subsite; S1 Fig) and the cofactor maintains the extended conformation typically found in dehydrogenases [20]. In contrast, in V. cholera IMPDH (VcIMPDH), the adenine ring binds to the adjacent monomer and interacts with a different set of residues (referred to as the A^B-subsite; S1 Fig) and the cofactor assumes a rare compact conformation [21]. It also appears that adenine binding to this site is less constrained because two different conformations are observed for this moiety in two crystal structures of VcIMPDH[21]. This provides critical information that the design of bacteria-selective
inhibitors should focus on the A\textsuperscript{B}-subsite. Importantly, compounds that bind with high affinity to this site should not bind to human IMPDHs.

Bacterial IMPDH-specific compounds were discovered in a high throughput screen for inhibitors of Cryptosporidium parvum IMPDH (CpIMPDH). Although C. parvum is a protozoa, its IMPDH is a bacterial-like IMPDH [22]. Multiple potent chemotypes have been developed as inhibitors of this enzyme (designated as classes A, C, D, N, P, and Q, among others) [23–29]. These inhibitors target the A\textsuperscript{B}-subsite and thus show high selectivity for bacterial IMPDHs. Moreover, structural studies of CpIMPDH with representatives from two classes, C\text{64} and Q\text{21}, identified an “inhibitor minimal structural motif” (IMSM) consisting of A165 and Y358’ (prime denotes a residue from the adjacent monomer) that is required for compound binding [27,30–32]. Bacterial IMPDHs have high sequence similarities and the IMSM motif is found in many species, including Mt\text{b}IMPDH2 with A285/Y487’ in the corresponding positions. However, despite this sequence conservation, the structure–activity relationships (SAR) of a given inhibitor chemotype are not preserved between different bacterial IMPDHs, thus structure-based compound optimization toward a given IMPDH cannot be performed by simple knowledge-based prediction, but requires experimental verification [21,31,32].

Numerous efforts by several groups in academia and industry directed at characterization of either apo or ligand-bound Mt\text{b}IMPDH2 structures have been unsuccessful, likely due to the very low solubility of the recombinant Mt\text{b}IMPDH2 protein expressed in E. coli. We have overcome this major limitation by designing a variant that lacks the non-catalytic CBS subdomain (Mt\text{b}IMPDH2\text{Δ}CBS), greatly improving solubility [21] without impacting enzyme catalytic properties. Here we present the first crystal structures of Mt\text{b}IMPDH2\text{Δ}CBS, including the apoenzyme, the E\textenu{X}M\textenu{P}+NAD\textsuperscript{+} complex, and complexes with IMP and three inhibitors, MAD\text{1}, P\text{41}, and Q\text{67} (Fig 1C). In addition, we report the SAR for Mt\text{b}IMPDH2\text{Δ}CBS inhibition along with antibacterial activity of several inhibitors from structurally distinct classes.

Results

Engineering IMPDH for inhibitor and structural studies

Deletion of IMPDH CBS domains facilitated crystallization of enzymes from several other organisms [21], therefore we constructed a variant of Mt\text{b}IMPDH2 wherein residues E126-R252 were replaced with a GG linker. The Mt\text{b}IMPDH2\text{Δ}CBS showed significantly improved solubility and crystallizability properties[21] with the steady state kinetic parameters comparable to those reported for the wild type enzyme (Table 1 [16]). Similar results were reported recently for deletion mutants of three other bacterial IMPDHs [21]. Notably, the values of $K_m$ for both IMP and NAD$^+$ for Mt\text{b}IMPDH2 are significantly higher than those of the human enzymes, illustrating the functional differences between bacterial and human IMPDHs (Table 1 [33–36]).

Antitubercular activity of CpIMPDH inhibitors

We tested 139 compounds developed in our CpIMPDH inhibitor program for antitubercular activity [21,24,25,27–30,32,37,38], including compounds from the A benzotriazole (21), C benzimidazole (9), D phthalazinone (19), P urea (52) and Q benzoxazole (37) structural series (S1–S7 Tables). Most of these compounds were expected to be potent inhibitors of Mt\text{b}IMPDH2 based on their behavior versus CpIMPDH and Bacillus anthracis IMPDH (BaIMPDH; S1–S8 Tables).

Five P compounds and twelve Q compounds displayed significant activity against Mt\text{b} strain H37Rv in minimal BSA-free medium (MIC $\leq$20 $\mu$M, Fig 2, Tables 2 and 3). The compounds were somewhat less effective in BSA-supplemented rich media (Table 2). No active
The active compounds have significantly more polar surface area (average topological polar surface area (tPSA) 83 ± 18 Å²) than the inactive compounds (average tPSA = 64 ± 4 Å², p < 0.001). The active and inactive compounds have similar hydrophobicity (average cLogP = 4.1 ± 0.8 for the active versus cLogP = 4.4 ± 1.3 for the inactive). All of the active compounds were potent inhibitors of \textit{Mtb} IMPDH2ΔCBS, with values of \( K_i^{\text{app}} \) ranging from 13–2000 nM (Table 2). Notably, P67 and Q67 are the most potent inhibitors of \textit{Mtb} IMPDH reported to date.

Several observations suggest that antitubercular activity results from inhibition of \textit{Mtb} IMPDH2. First, (S)-isomers of the Q compounds inhibit bacterial IMPDHs, while the (R)-isomers are inactive [27]. The racemate Q60 has approximately half the antitubercular activity as the (S)-isomer Q67, as expected if \textit{Mtb} IMPDH2 is the target (S7 Table). The values of MIC for ten active compounds, including all the P compounds, increased by at least a factor of 4 in the presence of guanine. This rescue provides strong evidence for the on-target activity of the compounds due to inhibition of \textit{Mtb} IMPDH2 in the bacteria. The values of MIC increased by lesser extents for the remaining compounds (Q9, Q22, Q27, Q42, Q46, Q49, Q59). These compounds may also engage another target. Lastly, antitubercular activity correlated roughly with the potency of \textit{Mtb} IMPDH2ΔCBS inhibition (Table 2 and S3 Fig).

All five P compounds also displayed antibacterial activity against \textit{B. anthracis} (S8 Table [37]). Of the eight Q compounds also tested against \textit{B. anthracis}, only Q67 displayed activity against both bacteria. While P32 and Q67 have similar activity against both bacteria, P41 and P67 are 5-7-fold more effective against \textit{Mtb} and P146 and P150 are 15-28-fold more effective against \textit{B. anthracis}. Differences in the SARs for enzyme inhibition cannot simply account for these differences in antibacterial activity (S8 Table and S2 Fig). Therefore, differences in cellular accumulation likely determine antibacterial spectrum. Interestingly, the compounds active

\begin{verbatim}
|                  | \textit{Mtb} IMPDH2ΔCBS | \textit{Mtb} IMPDH2\textsuperscript{a} | hIMPDH1 | hIMPDH2 |
|------------------|------------------------|---------------------------|---------|---------|
| Km (IMP), μM     | 41 ± 4                 | 78 ± 6                    | 14–18\textsuperscript{b,c,d} | 4–9\textsuperscript{b,c,e} |
| Km (NAD\textsuperscript{+}), μM | 580 ± 30              | 1005 ± 95                 | 42–70\textsuperscript{b,c,d} | 6–32\textsuperscript{b,c,e} |
| Kii (NAD\textsuperscript{+}), mM | 16 ± 1                | 5.0 ± 0.6                 | 2.0 ± 0.6\textsuperscript{d} | 0.59 ± 0.02\textsuperscript{e} |
| kcat, s\textsuperscript{−1} | 0.57 ± 0.01            | 0.53 ± 0.03               | 1.2–1.8\textsuperscript{b,c,d} | 0.4–1.4\textsuperscript{b,c,e} |
\end{verbatim}

\textsuperscript{a}Reference [16]  
\textsuperscript{b}Reference [33]  
\textsuperscript{c}Reference [94]  
\textsuperscript{d}Reference [95]  
\textsuperscript{e}Reference [96]

\textit{doi:10.1371/journal.pone.0138976.t001}

Fig 2. General structures of \textit{Cp} IMPDH inhibitors from P and Q series. Modular structure of (A) P compounds and (B) Q compounds. Substituents X, Y, R\textsubscript{1} and R\textsubscript{2} are listed in Table 3. Designation “5” and “6” refers to the position in the benzoxazole ring of Q compounds.

\textit{doi:10.1371/journal.pone.0138976.g002}
Table 2. Antitubercular activity of CpIMPDH inhibitors. The values of $K_{\text{app}}$ for inhibition of MtbIMPDH2ΔCBS.

| Cmpd | $K_{\text{app}}$ (nM) | cLogP | tPSA (Å$^2$) | MIC in GAST media | MIC in 7H9 media |
|------|-------------------------|-------|-------------|-------------------|-----------------|
|      | - Gua MIC (μM) | N | + Gua MIC (μM) | N | - Gua MIC (μM) | N | + Gua MIC (μM) | N |
| P32  | 158 $^b$         | 2.4  | 116.8       | 11.4 ± 5.3 | 4 | ≥40 | 3 | 27.2 ± 15.7 | 4 | ≥38 | 3 |
| P41  | 17 ± 4           | 4.56 | 61.4        | 5.0 ± 3.1  | 4 | ≥40 | 3 | 33.3 ± 13.5 | 4 | ≥38 | 3 |
| P67  | 13 ± 5           | 3.34 | 94.0        | 2.9 ± 0.4  | 3 | ≥40 | 3 | 15.7 ± 5.5  | 3 | 19 ± 6 | 3 |
| P146 | 37 ±8            | 3.53 | 103.3       | 14.9 ± 10.0| 2 | >50 | 1 | 28.0 ± 9.0  | 2 | 44 ± 7 | 2 |
| P150 | 35 ± 3           | 4.42 | 94.03       | 14.2 ± 5.0 | 2 | >50 | 1 | 43.5 ± 6.0  | 2 | 63 ± 13 | 2 |
| Q7   | 650 ± 140        | 3.59 | 72.3        | 17.5 ± 7.0 | 2 | 50  | 1 | 28.0 ± 19.2 | 3 | ≥37 | 2 |
| Q22  | 2000 ± 60 $^c$   | 5.18 | 72.3        | 19.8 ± 14.9| 3 | 25 ± 12| 2 | 25.3 ± 8.3  | 4 | 50 ± 40| 3 |
| Q27  | 240 ± 40         | 4.21 | 72.3        | 15.2 ± 8.2 | 4 | 38 ± 12| 3 | 19.1 ± 13.3 | 4 | 60 ± 40| 3 |
| Q33  | 150 ± 50         | 3.68 | 81.5        | 5.3 ± 0.9  | 3 | 24 ± 16| 3 | 10.4 ± 1.8  | 3 | 21 ± 4 | 3 |
| Q36  | 76 ± 27 $^c$     | 4.85 | 72.3        | 9.4 ± 3.0  | 2 | 37   | 1 | 15.8 ± 5.5  | 3 | 28 ± 9 | 2 |
| Q42  | 620 ± 70         | 2.97 | 90.7        | 17.3 ± 4.1 | 5 | 41 ± 6 | 4 | 22.0 ± 9.1  | 5 | 31 ± 7 | 4 |
| Q46  | 130 ± 40         | 4.01 | 124.1       | 11.6 ± 5.7 | 4 | 38 ± 12| 3 | 19.5 ± 4.1  | 4 | 44 ± 7 | 2 |
| Q49  | 440 ± 40         | 3.61 | 63.1        | 12.7 ± 5.3 | 3 | 31 ± 19| 2 | 21.1 ± 11.6 | 4 | 31 ± 6 | 3 |
| Q59  | 40 ± 7           | 4.85 | 72.3        | 9.7 ± 4.1  | 4 | 26 ± 12| 3 | 9.1 ± 3.1   | 4 | 25 ± 20| 3 |
| Q60  | 40 ± 16          | 5.02 | 75.1        | 14.5 ± 4.0 | 2 | >50  | 1 | 14.5 ± 4.8  | 3 | 19 ± 0 | 2 |
| Q67  | 14 ± 3           | 5.02 | 75.1        | 6.7 ± 3.0  | 2 | 50   | 1 | 11.8 ± 6.3  | 3 | 35 ± 15| 2 |
| Q77  | 100 ± 20         | 4.21 | 72.3        | 6.3 ± 3.0  | 2 | 37   | 1 | 11.0 ± 2.0  | 2 | 19 ± 0 | 2 |
| MAD1 | 1580 ± 70 $^d$   | 1.57 | 209         | 100 $^a$   | 1 | >100 $^a$ | 1 | 50          | 1 | 75  | 1 |

$^a$. Average and standard deviation of three independent determinations unless otherwise noted.
$^b$. n = 1.
$^c$. n = 2.
$^d$. $K_{\text{app}}$ of 1500 nM was determined for inhibition of wild-type MtbIMPDH2 reported in [16]
$^e$. MIC determined after two weeks.

doi:10.1371/journal.pone.0138976.t002

Table 3. Structures of CpIMPDH inhibitors with antitubercular activity.

| P compound | X     | Y     | Q compound | R₁   | X     | Y     | Connection | R₂ |
|------------|-------|-------|------------|------|-------|-------|------------|----|
| P32        | NOH   | NH₂   | Q9         | Ph   | O     | CH₃   | 5          | 4-Py |
| P41        | CH₃   | N(CH₃)₂| Q22        | 2,4-di-ClPh | O   | CH₃   | 5          | 2-Py |
| P67        | NOH   | N(CH₃)₂| Q27        | 2-ClPh | O    | CH₃   | 5          | 4-Py |
| P146       | NOH   | 4-morpholinyl | Q33       | 4-0CH₃Ph | O   | CH₃   | 5          | 4-Py |
| P150       | NOH   | N(CH₂CH₃)₂| Q36       | 2,3-di-ClPh | O   | (S)-CH₃ | 5          | 4-Py |
| Q42        | 2,3-di-0CH₃Ph | O    | (S)-CH₃   | 5          | 4-Py |
| Q46        | 2-Cl,3-NO₂Ph | O    | (S)-CH₃   | 5          | 4-Py |
| Q49        | Ph    | (S)-CH₃ | 5          | 4-Py |
| Q59        | 2,3-di-ClPh | O    | (S)-CH₃   | 6          | 4-Py |
| Q60        | 2,3-di-ClPh | NH   | CH₃        | 5          | 4-Py |
| Q67        | 2,3-di-ClPh | NH   | (S)-CH₃   | 5          | 4-Py |
| Q77        | 2-ClPh | O     | (S)-CH₃   | 5          | 4-Py |

doi:10.1371/journal.pone.0138976.t003
against *B. anthracis* are significantly less hydrophobic than those active against *Mtb* (cLogP = 3.5 ± 0.5, p = 0.018; S8 Table [37]).

The five active P compounds contain a 3-carboxamido-4-chlorophenyl ring. Remarkably, the 4-chloro substituent is also found in 21 inactive P compounds, suggesting that the 3-carboxamido-4-chlorophenyl ring is critical for antitubercular activity. The 3-piperazinylcarbonyl-4-chloro analog Q94 is inactive, suggesting that the positive charge is deleterious (S5 Table). The inactive compounds include the alkene analog of P32 (P16), the ketone analog of P32 (P25) and methyloxime analog of P67 (P74). P16, P25 and P74 are also expected to be good inhibitors of *Mtb*IMPDH2, which suggests that the oxime group confers an advantage for cellular accumulation.

All of the active Q compounds except Q22 contain the 2-(pyrid-4-yl)benzoxazole group, which largely reflects the SAR of enzyme inhibition for *Cp*IMPDH and the consequential predominance of this group in the Q pool (70%). Nine of the active Q compounds contain a 2-chloro-substituted phenyl ring, and five of these are 2,3-dichloro substituted. Q58 and Q64 are the only two inactive compounds that contain 2,3-dichlorophenyl group. Q58 is the 2-(thiazol-2-yl)benzoxazole analog of the active compound Q36, while Q64 is the 2-(thiazol-5-yl)benzoxazole analog of the active compound Q59. These substitutions are expected to decrease the potency of enzyme inhibition by a factor of 4–20 based on *Cp*IMPDH and *Ba*IMPDH data (S8 Table). Therefore the 2,3-dichlorophenyl group is important for antitubercular activity in the benzoxazole scaffold.

**Mechanism of *Mtb*IMPDH2ΔCBS inhibition**

Although the *Cp*IMPDH inhibitors all bind in the cofactor site, their mechanisms of inhibition can vary depending on their relative affinities for the E•IMP and E•XMP⁺ complexes. Therefore we determined the mechanism of inhibition for the representative antitubercular compounds P41 and Q67, as well as for compound MAD1, the first reported inhibitor of *Mtb*IMPDH2 [16] (Fig 1C). MAD1 is a third generation mycophenolic adenine nucleotide (MAD) inhibitor [16,39,40] that bears the closest resemblance to NAD⁺ (Fig 1). All three compounds are uncompetitive inhibitors with respect to IMP as expected, implying interactions with the base of IMP are critical for binding (S9 Table). The mechanism of inhibition with respect to NAD⁺ varies among the three compounds (S9 Table). MAD1 is an uncompetitive inhibitor, suggesting that this compound has a strong preference for the E•XMP⁺ intermediate. P41 is a noncompetitive inhibitor, indicating this compound has similar affinity to both E•IMP and E•XMP⁺. Q67 is a competitive inhibitor versus NAD⁺, suggesting that it has a strong preference for E•IMP.

**Overall structure**

Five high resolution crystal structures were obtained for *Mtb*IMPDH2ΔCBS (Table 4). These include the apo form, the XMP•NAD⁺ complex, and three IMP•inhibitor complexes (E•IMP•I) with MAD1, P41, and Q67. The structure of the tertiary complex of *Mtb*IMPDH2ΔCBS with XMP and NAD⁺ was obtained by soaking crystals containing the *Mtb*IMPDH2ΔCBS•IMP complex with 200 mM NAD⁺. Structures of protein-inhibitor complexes were obtained by co-crystallization with IMP and inhibitor. In all five structures, the first 26 or 27 N-terminal residues are disordered in every protein chain. An approximately 20-residue portion of the active site flap is also disordered, as observed for the majority of the IMPDH structures reported to date.
Table 4. Data collection and refinement statistics.

|                       | MtbIMPDH2∆CBS | MtbIMPDH2∆CBS+IMP-MAD1 | MtbIMPDH2∆CBS+IMP-P41 | MtbIMPDH2∆CBS+IMP-Q67 | MtbIMPDH2∆CBS+IMP-NAD* |
|-----------------------|---------------|------------------------|-----------------------|-----------------------|------------------------|
| **Data collection**   |               |                        |                       |                       |                        |
| Space group           | P1            | I4                     | I4                    | I4                    | I4                     |
| Cell dimensions       |               |                        |                       |                       |                        |
| a, b, c (Å)           | 75.22, 75.23, 75.28 | 88.23, 88.23, 84.63 | 87.94, 87.94, 84.76 | 88.25, 88.25, 84.27 | 88.15, 88.15, 85.51 |
| a, b, γ (°)           | 108.3, 108.3, 111.9 | 108.3, 108.3, 111.9 | 108.3, 108.3, 111.9 | 108.3, 108.3, 111.9 | 108.3, 108.3, 111.9 |
| Protein molecules/ASU | 4             | 1                      | 1                     | 1                     | 1                      |
| Temperature (K)       | 100           | 100                    | 100                   | 100                   | 100                    |
| Radiation source      | APS, 19-ID    | APS, 19-ID             | APS, 19-ID            | APS, 19-ID            | APS, 19-ID             |
| Wavelength (Å)        | 0.97918       | 0.97999                | 0.97999               | 0.97999               | 0.97918                |
| Resolution (Å)^a      | 35.73–1.70 (1.73–1.70) | 35.76–1.90 (1.93–1.90) | 35.67–2.00 (2.03–2.00) | 30.47–1.76 (1.79–1.76) | 35.80–1.60 (1.63–1.60) |
| Unique reflections    | 123936 (3628) | 24204 (779)           | 21407 (938)           | 31906 (1555)          | 42708 (1975)           |
| R_{merge}^b           | 0.056 (0.330) | 0.105 (0.326)         | 0.130 (0.762)         | 0.089 (0.644)         | 0.075 (0.805)          |
| I/σ(I)                | 17.22 (6.6) | 11.7 (2.1)            | 8.2 (1.8)             | 10.6 (2.0)            | 29.0 (1.81)            |
| Completeness (%)      | 91.4 (51.5)  | 94.5 (61.0)           | 98.0 (86.1)           | 99.7 (97.5)           | 99.5 (93.1)            |
| Redundancy            | 2.2 (1.8)    | 4.2 (2.5)             | 3.9 (2.1)             | 4.4 (2.7)             | 5.8 (4.0)              |
| **Refinement**        |               |                        |                       |                       |                        |
| Resolution (Å)^a      | 35.73–1.70 (1.71–1.70) | 35.76–1.90 (1.96–1.90) | 35.67–2.00 (2.09–2.00) | 30.47–1.76 (1.81–1.76) | 35.80–1.60 (1.64–1.60) |
| Reflections: work/ test set^a | 122867/6432 (2097/117) | 23811/1272 (2103/117) | 20300/1090 (2219/109) | 30282/1619 (2437/130) | 40394/2185 (2343/103) |
| R_{work}/R_{free}^c  | 0.151/0.183 (0.242/0.269) | 0.143/0.189 (0.219/0.286) | 0.178/0.221 (0.282/0.338) | 0.153/0.179 (0.239/0.250) | 0.160/0.191 (0.231/0.286) |
| No. of atoms:protein/ligands/water | 11793/170/793 | 2585/84/169 | 2527/51/118 | 2840/64/188 | 2386/68/161 |
| Average B factor (Å^2): protein/ligands/water | 28.8/35.7/45.8 | 27.4/37.9/34.2 | 52.2/40.7/48.8 | 31.2/30.9/39.1 | 30.5/28.8/35.2 |
| Bond lengths (Å)      | 0.010         | 0.010                  | 0.007                 | 0.007                 | 0.009                  |
| Bond angles (°)       | 1.282         | 1.380                  | 1.209                 | 1.169                 | 1.325                  |
| Most favored          | 98.4          | 97.5                   | 97.7                  | 98.6                  | 98.2                   |
| Outliers              | 0.0           | 0.0                    | 0.0                   | 0.0                   | 0.0                    |
| PDB accession code   | 4ZQR          | 4ZQP                   | 4ZQN                  | 4ZOO                  | 4ZQM                   |
| **Crystallization conditions** | 0.1M sodium/potassium phosphate pH 6.2, 25% 1,2-propandiol, 10% glycerol, 16°C | 0.1M sodium/potassium phosphate pH 6.2, 25% 1,2-propandiol, 10% glycerol, 16°C | 0.3M magnesium formate, 0.1M Tris pH 8.5, 16°C | 0.1M sodium/potassium phosphate pH 6.2, 25% 1,2-propandiol, 10% glycerol, 16°C | 0.4M magnesium formate, 0.1M TES-HCl pH 8.5, 20% sucrose, 16°C, soaked with 200 mM NAD |

ASU, Asymmetric Unit,

^aValues in parentheses correspond to the highest-resolution shell.

^bR_{merge} = \sum hkl |I(hkli)−\langle I(hkli)\rangle|/\sum hkl \langle I(hkli)\rangle, where I(hkli) is the intensity for the ith measurement of an equivalent reflection with indices h, k, and l.

^cR_{work} = \sum obs |F_{calc}−F_{obs}|/\sum obs |F_{calc}|, where F_{obs} and F_{calc} are observed and calculated structure factors, respectively. R_{free} is calculated analogously for the test reflections, which were randomly selected and excluded from the refinement.

^dLigands include all atoms excluding protein and water atoms.

doi:10.1371/journal.pone.0138976.t004
Structure of Apo MtbIMPDH2ΔCBS

The apo structure contains four polypeptide chains in the asymmetric unit (rmsds for Cα atoms of chain A versus other three are from 0.10 to 0.12 Å). A potassium ion is bound between subunits, interacting with six main chain carbonyls, three from the loop containing active site C341 (G336, G338, and C341) and three from the C-terminal portion of the adjacent subunit (E551, S512, and H513). This coordination is very similar to that observed in previously reported structures [21,41,42]. A phosphate ion originating from the crystallization buffer binds in the phosphate site of IMP, anchored by hydrogen bonding interactions with the backbone nitrogen atoms of S339, G376, G397 and S398 and the side chains of S339 and Y421. This interaction network is further supplemented by water-mediated contacts. Interestingly, K454 (residue in the active site flap) occupies the position where the linker portions of P41 and Q67 bind (see below, Fig 3A). This residue must move out of the active site when an inhibitor binds. Thus the conformational dynamics of the active site flap may contribute to the differences in inhibitor affinities among IMPDHs from different sources.

MtbIMPDH2ΔCBS complex with XMP and NAD+

The 1.60 Å resolution crystal structure of the product/cofactor complex contains one protein chain per asymmetric unit. Although no potassium was present in the crystallization buffer and this ion is not found in the complex, the high quality electron density maps clearly show that the product XMP is present in the active site (Fig 3B). This indicates that the enzyme in the crystal is catalytically competent. XMP is in essentially the same orientation as observed previously in IMPDH from V. cholerae (PDB id 4X3Z) [21]. The xanthine ring contacts C341, T343, M424, G425, and E458 and also has water-mediated interactions with the main chain nitrogen atom of G336 (Fig 3B). The phosphate group of XMP interacts with S339, G376, G397, S398, and Y421, and the sugar moiety forms hydrogen bonds with D374. These residues are highly conserved in all IMPDHs, with the exception of E458, which is replaced by glutamine in eukaryotic IMPDHs.

As observed for VcIMPDHΔCBS•XMP•NAD+ [21], the NAD+ adenosine moiety binds in the A8+-subsite located at the subunit interface and interacts with residues from both monomers (Fig 3C and 3D). For comparison, binding of adenosine in the A5+-subsite of the hIMPDH2 complex with NAD+ and a substrate analog, CPR (hIMPDH2•CPR•NAD+; PDB code 1NFB) is shown in Fig 3E. In MtbIMPDH2ΔCBS•XMP•NAD+ the adenine ring is in the anti-orientation with respect to the sugar ring. The adenine N3A atom contacts the side chain of N289, whereas the N6A amine makes one hydrogen bond with the carbonyl group of A483' and one water-mediated contact with the side chain of E458. In addition, one side of the adenine ring participates in van der Waals interactions involving V60' and P61' and the other side π/π stacks with H286 in an edge-to-face orientation (Fig 3C). The same set of interactions is present in VcIMPDHΔCBS•XMP•NAD+, although VcIMPDH has S256 in place of N289, L26' instead of V60' and the π/π stacking with the conserved histidine residue occurs in a face-to-face orientation. The N6A amine also makes a NH2/π interaction with the side chain of Y487' (part of the ISMS) in MtbIMPDH2ΔCBS. This contact is not present in VcIMPDHΔCBS•XMP•NAD+ because VcIMPDH has L446' in place Y487' (Fig 3D). It is also important to note the adenosine portion in MtbIMPDH2ΔCBS•XMP•NAD+ is positioned deeper into the binding pocket than in VcIMPDHΔCBS•XMP•NAD+ and the cofactor is in a more compact orientation (C6A-C2N distance of 9.16 Å in MtbIMPDH2ΔCBS•XMP•NAD+ versus 11.41 ± 0.11 Å in VcIMPDHΔCBS•XMP•NAD+ [21,43]). Interestingly, the position of the adenine group in MtbIMPDH2ΔCBS•XMP•NAD+ is more similar to the VcIMPDHΔCBS structure with NAD+ and a mixture of IMP and a covalent intermediate (VcIMPDHΔCBS•IMP•NAD+; PDB id
Fig 3. Active site flap in apo MtbIMPDH2ΔCBS and cofactor orientation in MtbIMPDH2ΔCBS-XMP-NAD⁺ complex. (A) Overlay of apo MtbIMPDH2ΔCBS and MtbIMPDH2ΔCBS-IMP-P41 structures with a flap residue K454 in the apo form clashing with the linker position of P41, indicating that these two elements occupy the same space in the active site. For MtbIMPDH2ΔCBS-IMP-P41, only residues (lines) and P41 (sticks) are shown; color code for MtbIMPDH2ΔCBS as in Fig 5A. For the apo structure, chains A (lime) and C (gray) are shown in a cartoon representation and residues corresponding to these involved in inhibitor binding are shown as lines. A prime denotes a residue from the adjacent monomer. (B) Top view of the active site showing XMP.
interactions. Chain A (slate blue) and symmetry-generated adjacent chain (violet) are shown. Residues are represented as lines. XMP (pale yellow) and NAD$^+$ (green) are shown as sticks. (C) Side view of the active site detailing NAD$^+$ binding. Color code and depiction as in panel (B). For panels (B) and (C) 2mFo-DFc electron density maps contoured at the 2$\sigma$ level for XMP (pale yellow) and 1.5 $\sigma$ level for NAD$^+$ (green) are shown on the right. Atoms discussed in text are labeled. (D) Cofactor position in superimposed structures $\Delta$MtbIMPDH2\DeltaCBS•XMP•NAD$^+$ and $\Delta$VcIMPDH\DeltaCBS•XMP•NAD$^+$. Only ligands (depicted as sticks) and the interacting residues (represented as lines) are shown. Residues are labeled according to $\Delta$MtbIMPDH2 numbering with $\Delta$VcIMPDH numbering in parentheses. Color code is as follows: for the $\Delta$Mtb structure as in panel (A); for the Vc structure: chain A (light orange), symmetry-generated adjacent chain (brown), NAD$^+$ (orange), XMP and selected hydrogen bonds are omitted for clarity. (E) Overlay of the cofactor position in $\Delta$MtbIMPDH2\DeltaCBS•XMP•NAD$^+$ and the ternary complex of $\Delta$hIMPDH2 with NAD$^+$ and substrate analog, CPR (hiIMPDH2\DeltaCBS•NAD$^+$; PDB code 1nfb). Residues are labeled according to $\Delta$MtbIMPDH2 numbering with $\Delta$VcIMPDH2 numbering in parentheses. Color code is as follows: for the $\Delta$Mtb structure as in panel (B); for the human structure: chain A (light gray), symmetry-generated adjacent chain (dark gray), NAD$^+$ (gray), CPR is omitted for clarity. Localization of the eukaryotic A$^\beta$-subsite and the bacterial A$^\alpha$-subsite is indicated. For all panels (where applicable): a prime denotes a residue from the adjacent monomer. Water molecules are shown as red spheres. Hydrogen bonds are depicted as red dashed lines.

doi:10.1371/journal.pone.0138976.g003

4QNE [21]). The cofactor in VcIMPDH\DeltaCBS\Delta\DeltaIMP•NAD$^+$ has similarly compact conformation (C6A-C2N distance of 9.42 ± 0.10 Å), with the adenine ring in an anti-conformation. Perhaps NAD$^+$ changes orientation during the catalytic cycle prior to its dissociation from the active site, as suggested for $\Delta$VcIMPDH [21].

The interactions of the NAD$^+$ pyrophosphate are similar to those in previously reported cofactor structures. R108 makes two direct hydrogen bonds to O3 and O2A of the phosphate moiety and the same phosphate group makes one direct hydrogen bond to the amido group of A285 (part of the IMSM) and water-mediated bonds to the main chain amido and carbonyl groups of V261. The corresponding interactions, except for R108-O3/O2A, are also found in $\Delta$VcIMPDH\DeltaCBS•XMP•NAD$^+$ [21].

The nicotinamide ring of NAD$^+$ stacks against the xanthine ring of XMP and the nicotinamide ribose is anchored via hydrogen bonds between the hydroxyl groups and the conserved D283, as observed previously in other IMPDHs (Fig 3C). However, the orientation of the nicotinamide portion is opposite from that observed in other cofactor complexes. In VcIMPDH\DeltaCBS•XMP•NAD$^+$, the nicotinamide ring is in the anti-conformation (Fig 3D) and the carboxamide group makes hydrogen bonds with two conserved glycine residues [21,44]. This conformation is consistent with hydride transfer to the pro-S position of NAD$^+$ [45,46]. However, the nicotinamide ring flips ~180° and is in a syn-conformation in $\Delta$MtbIMPDH2\DeltaCBS•XMP•NAD$^+$ (with $\chi_N$ torsion angle of 5.7°; Figs 1B and 3C). The carboxamide moiety makes direct hydrogen bonds with side chains of T343, E458, and Y487 (which is a part of the IMSM) and a water-mediated interaction with the O1N atom of the phosphate group and the N7A atom of adenine (Fig 3C and 3D). The carboxamide group also makes van der Waals contacts with A285 (also a part of the IMSM). As a result of the syn-conformation, the pro-R side of the nicotinamide ring now faces IMP with its C4N carbon aligned with the C2 of the IMP hypoxanthine ring (C4N-C2 distance of 3.28 Å).

We characterized the reaction of $^2$H-IMP and NAD$^+$ to determine if the stereochemistry of hydride transfer catalyzed by $\Delta$MtbIMPDH\DeltaCBS was pro-R as suggested by the crystal structure. As reported previously [45,46], $\Delta$hIMPDH2 transferred deuterium to the pro-S position of NAD$^+$ (S4 Fig). The deuterium also transferred to the pro-S position of NAD$^+$ in the $\Delta$MtbIMPDH2\DeltaCBS catalyzed reaction (S4 Fig). These observations indicate that the orientation of NAD$^+$ observed in the XMP complex is not competent for hydride transfer and may reflect cofactor conformation stabilized by the IMSM.
Inhibitor binding

Each structure MtbIMPDH2ΔCBS-inhibitor complex contains one protein chain per asymmetric unit with one molecule of IMP and one molecule of inhibitor bound. The active sites are ordered and the electron densities for ligands and protein are well defined (Figs 4 and 5). The overall structures of the inhibitor complexes are very similar, with r.m.s.d. for Cα atoms of A chains ranging from 0.23 to 0.46 Å. The structures of complexes with MAD1 and Q67 contain a potassium ion, as described for the apo protein. The crystallization buffer used to obtain the IMP•P41 did not contain potassium ions (Table 4). The protein-IMP interactions are analogous to those described above for XMP, as well as for previously determined structure of IMP complexes [21,27,29,30], and will not be discussed further.

The inhibitors have modular structures consisting of two aromatic moieties connected by different linkers (1,2,3-triazole in MAD1, urea in P41 and an amide in Q67) (Fig 1C). One aromatic portion of the inhibitor stacks against the hypoxanthine ring of IMP and interacts with residues within the nicotinamide-binding subsite (the "leftside" rings, Fig 1C). The other aromatic moiety interacts with IMSM residue Y487' in the Aβ-subsite (the "rightside" rings; Fig 1C) and the linker bends around IMSM residue A285. Specific interactions for each inhibitor will be described below.

MtbIMPDH2ΔCBS•IMP•MAD1 complex

MAD1 is a mycophenolic acid-adenosine conjugate initially designed to target human IMPDHs [16]. It was the first reported inhibitor of MtbIMPDH2, although it is a much more potent inhibitor of the human enzymes. Other mycophenolic acid-adenosine conjugates with varying linkers did not inhibit MtbIMPDH2. The mycophenolic acid-derived moiety interacts with IMP and forms hydrogen bonds with T343, G334 and G336 (Fig 4A). These residues are conserved in all IMPDHs and the corresponding interactions are also present in eukaryotic enzymes (for example, in the E-XMP•mycophenolic acid complex of Chinese hamster IMPDH2 (PDB id 1JR1) [41]). MAD1 does not interact with E458, in contrast to the CpIMPDH inhibitors (see below). The absence of these contacts may account for the relatively low affinity of this compound (S9 Table). The triazole linker of MAD1 engages in hydrogen bonding interaction via the N3 atom with the main chain amide nitrogen atom of A285, while the remainder of the triazole makes van der Waals contacts with R108 and T284 (Fig 4A). The position of the adenosine portion of MAD1 in the Aβ-subsite is superimposable with the position of the adenosine moiety of NAD⁺ in the XMP•NAD⁺ complex. Consequently, interactions with H286, N289, V60’, P61’, A483’ and Y487’ are maintained (Fig 4B). Thus, MAD1 adopts an orientation analogous to the folded cofactor conformation that is preferred in bacterial IMPDHs.

The divergence of the cofactor binding sites in bacterial and eukaryotic enzymes is illustrated by comparing the structures of the MtbIMPDH2ΔCBS•IMP•MAD1 with hIMPDH2 in complex with another MAD inhibitor, C2-MAD, and ribavirin 5’-monophosphate (RVP) (PDB id 1NF7; doi:10.2210/pdb1nf7/pdb [39]). C2-MAD is a second generation mycophenolic adenine analogue that has a methylenebis(phosphonate) linker. The linker and mycophenolic acid-derived portions of the inhibitors are positioned similarly in both enzymes. However, the adenosine portion of C2-MAD rotates away from the subunit interface and binds in the Aβ-subsite (Fig 4C). The C2-MAD adenine ring π/π stacks between the side chains of H253 and F282 (hIMPDH2 numbering) located within a single monomer (Fig 4C). Thus, C2-MAD assumes an orientation analogous to the extended NAD⁺ conformation preferred in eukaryotic IMPDHs (Fig 3E). Therefore, interaction of the adenine moiety with the Aβ-subsite may account for higher affinity of MAD inhibitors with eukaryotic IMPDHs.
P41 has a urea linker connecting the 3-isoprenyl-α,α-dimethylbenzyl (left side ring) and 4-chloro-3-N,N-dimethylbenzamide [26] (right side ring; Fig 1C). The hypoxanthine ring of IMP interacts with the sp² center and the aromatic centroid of the left side ring (Figs 1C and 5A). Both nitrogen atoms of the urea linker form hydrogen bonds with the side chain of E458 (N1/P41—OE2/E458 and N2/P41—OE2/E458 distances of 3.27 and 3.08 Å, respectively) (Fig 5A). The interactions with E458 are observed in other inhibitor complexes and are likely to be important for inhibitor potency [21,27,29,30]. Within the A⁵⁸-subsite, the right side ring interacts with the ring of Y487 in an orientation that is midway between face-to-face and edge-to-face geometries. The right side ring also makes contacts with H286, V60', and P61'.

The importance of the 4-chloro substituent for antitubercular activity can be explained by the presence of a pair of orthogonal halogen/hydrogen bonds [47,48]. The Cl atom interacts...
Fig 5. Binding of CplIMPDH-selective inhibitors P41 and Q67. (A) MtbIMPDH2ΔCBS•IMP•P41 complex. (B) MtbIMPDH2ΔCBS•IMP•Q67 complex. Chain A (slate) and symmetry-generated adjacent chain (violet) are shown in a cartoon representation. Residues are shown as lines. A prime denotes a residue from the adjacent monomer. Molecules of IMP (light gray), P41 (magenta), and Q67 (orange) are shown as sticks. Water molecules are depicted as red spheres. Potential hydrogen and halogen bonds are shown as red dots.
with the carbonyl of G486’ (Cl/P41 – O/G486’ distance of 3.52 Å) (Fig 5A). This carbonyl also makes a hydrogen bond with the side chain of S57’ (O/G486’–OG/S57’ distance of 2.85 Å) at an angle of 90° relative to the halogen bond. The halogen substituent also contacts the imidazole ring of H286. The structure explains the diversity of carboxamide substitutions in the P compounds with antitubercular activity. The carboxamide group of P41 does not participate in any hydrogen bonds with the protein. The two methyl groups sit in a hydrophobic pocket formed by T284, V261, A285, N289, L291 and V292. These hydrophobic interactions can explain the higher affinity of substituted amides (Table 2, compare P34 and P67, P146 and P150).

**Mtb IMPDH2ΔCBS •IMP•Q67 complex**

Compound Q67 contains 2,3-dichloroaniline (left side ring) and 2-(4-pyridyl)-1,3-benzoxazole moieties (right side ring) connected with an amide linker [27] (Fig 1C). The leftside ring interacts with IMP via π/π stacking and C-X/π contacts involving the 2-chloro substituent. The 3-chloro substituent contacts the carbonyl atom of M424 and interacts with G425 (Fig 5B). These interactions explain the prevalence of the 2,3-dichloro substituents in the set of Q compounds with antitubercular activity. As in P41, the nitrogen atom of compound Q67 amide linker hydrogen bonds with one of the side chain oxygen atoms of E458 but the interaction for Q67 is stronger (2.79 Å versus 3.08 and 3.27 Å for P41).

As observed for the other inhibitors, the 4-pyridyl–1,3-benzoxazole moiety of Q67 is held in place by interactions with H286, V60’, P61’, and Y487’ in the A^B-site. In addition, Q67 makes several unique contacts: the N3 atom of the 1,3-benzoxazole group interacts with the main chain nitrogen atom of H286 and two water molecules connect the N4 atom of the 4-pyridyl substituent with the main chain nitrogen atom of R290 and the carbonyl oxygen atom of S57’ (Fig 5B). Similar water-mediated interactions involving the pyridyl moiety were previously observed in the structures of IMPDH and BaIMPDH complexes with another Q-series inhibitor, Q21 [21,27]. The additional interactions of chloro substituents, the short hydrogen bond with E458, and the network of water-mediated contacts can account for the high potency of Q67. The structure also explains why the stereochemistry of the linker is essential. The (S)-methyl group faces away from E458 and interacts with L455 and M430. The methyl group in the (R) isomer is most likely oriented towards E458 and thus disrupts the crucial hydrogen bond interaction between the amide linker and E458, making this isomer inactive.

**Discussion**

The structure of Mtb IMPDH2ΔCBS•XMP•NAD^+ confirms our recent findings that bacterial IMPDHs bind NAD^+ in an unusual compact conformation with the A^B-subsite located at the interface between two monomers. The different locations of the A^B and A^E sites account for the selectivity of the CpIMPDH inhibitors for bacterial IMPDHs. All high affinity CpIMPDH inhibitors bind to bacterial enzymes using the A^B site. In contrast, it appears that MAD inhibitors bind with high affinity to human IMPDH using the A^E site and with low affinity to bacterial enzymes using A^B site. Interestingly, the nicotinamide ring in the Mtb IMPDH structure is in a syn-conformation, which is not compatible with the pro-S hydride transfer observed in the reaction. Similar syn NAD(H) conformations have been observed among other pro-S stereospecific enzymes, such as transhydrogenase [49] and UDP-galactose 4-epimerase [50]. We link
the ability to bind the syn-conformation with the presence of the IMSM that is essential for inhibitor binding [10,30,31]. While hydride transfer cannot occur in the syn-conformation, it is possible that this conformation has another regulatory role.

New antibiotics to treat tuberculosis are urgently needed. Our work identifies inhibitors of \textit{Mtbi}MPDH2 with encouraging antitubercular activity. We also report the first crystal structures of this promising antimicrobial drug target, including the apo form and complexes with XMP/NAD\(^+\) and three structurally distinct inhibitors. These structures will greatly facilitate the further development of \textit{Mtbi}MPDH2-targeted antibiotics. Our \textit{Mtbi}MPDH2\(\Delta\)CBS inhibitor complexes provide important insights into the interactions that modulate affinity as well identify possible locations for further inhibitor optimization for both potency and cellular accumulation. Interactions with the hypoxanthine moiety of IMP, E458, and A\(^\text{B}\)-subsite are especially important for high affinity and selectivity. It is important to note that while the active site flap is partially disordered in all \textit{Mtbi}MPDH2\(\Delta\)CBS structures, different conformations of the flap are observed in the apo structure and the structures of the complexes. Thus, the flap may transiently interact with the inhibitor and these interactions may also contribute to inhibitor affinity.

\textbf{Material and Methods}

\textbf{Materials}

IMP was purchased from Acros Organics. NAD\(^+\) and NADH were purchased from Roche and Sigma, respectively. Tris, and common chemicals were purchased from Sigma. KCl and trichloroacetic acid were purchased from Fisher. \textit{Cp}IMPDH and \textit{Ba}IMPDH were purified as previously described [27,32]. The synthesis of the \textit{Cp}IMPDH inhibitors has been reported previously [23–25,27–30,37]. The synthesis of \textbf{MAD1} is described in [16]. Crystallization reagents were purchased from Hampton Research and Microlytic.

\textbf{Values of cLogP and tPSA}

Values of cLogP and tPSA were calculated in ChemBioDraw (Cambridgesoft Inc.). The relevant ionizations at pH 7.4 were included in the structures [37].

\textbf{Cloning}

The CBS domain deletion mutant (\textit{Mtbi}MPDH2\(\Delta\)CBS) was constructed via the megaprimer cloning method [51]. Wild type \textit{Mtbi}MPDH2 clone in vector pMCSG7 [27] was used as a template. The E126-R252 (\(\Delta\)CBS) deletion primer and the \textit{Mtbi}MPDH2 coding sequence forward primer were used to amplify a region of \textit{Mtbi}MPDH2-pMCSG7 ranging from the residue M1 to residue V261 with 5’ LIC overhang, while replacing codons for residues E126-R252 with codons for GG. The resulting product was used as a megaprimer in the whole plasmid synthesis reaction, with \textit{Mtbi}MPDH2-pMCSG7 as template and a reverse primer encoding 3’ end of \textit{Mtbi}MPDH2. KOD Hot Start DNA polymerase kit (EMD Millipore) was utilized in a PCR reaction. Cycling was performed at 95\(^\circ\) for 3 min, followed by 95\(^\circ\) for 40 sec, 53\(^\circ\) for 40 sec, 72\(^\circ\) for 1.5 min for 32 cycles. The PCR product was treated with T4 polymerase (Promega), annealed into pMCSG7 vector, transformed into \textit{E. coli} BL21(DE3) cells carrying the pMAGIC plasmid encoding rare \textit{E. coli} tRNA (Arg (AGA/AGG)) [52] and the resulting clone sequenced.

\textbf{Stereochemistry of hydride transfer}

[2-\(^2\)H]-IMP or [2-\(^1\)H]-IMP (2 mM) is mixed with NAD\(^+\) (2 mM) in assay buffer (50 mM d–11Tris, 150 mM KCl, 1 \(\mu\)M DTT, pD 8.0) in D\(_2\)O. \textit{Mtbi}MPDH (1 \muM) or hIMPDH2 (1.3 \muM) was added to initiate the reaction. After 2h incubation at room temperature, the protein was...
separated from small molecules by centrifugation using Amicon centrifugal filter (Millipore, 10K cutoff), and the small molecule mixtures were directly analyzed by 400MHz 1H NMR with water suppression using presaturation pulse.

**MIC determinations**

MIC is concentration that completely inhibits growth. Compounds MICs were determined as previously described [53]. MIC values were determined in at least triplicate according to the broth microdilution methods using compounds from DMSO stock solutions. Isoniazid was used as a positive control and DMSO was utilized as a negative control. Isolated *Mtb* cells (ATCC 27294) were cultured to an OD 0.2–0.3 in the required medium, then diluted to deliver approximately 1 x 10^4 bacteria per well of a 96 well clear round-bottom plate. Plates were read after 1 week with an inverted enlarging mirror plate reader and graded as either growth or no growth. GAST/Fe medium (per liter) consisted of 0.3 g of Bacto Casitone (Difco), 4.0 g of dibasic potassium phosphate, 2.0 g of citric acid, 1.0 g of L-alanine, 1.2 g of magnesium chloride hexahydrate, 0.6 g of potassium sulfate, 2.0 g of ammonium chloride, 1.80 ml of 10 sodium hydroxide, and 10.0 ml of glycerol, 0.05% Tween 80 and 0.05 g of ferric ammonium citrate adjusted to pH 6.6. 7H9/glycerol/glucose/BSA/Tween medium consisted of Middlebrook 7H9 broth base supplemented per liter with 0.2% glucose, 0.2% glycerol, 0.5% BSA fraction V, 0.08% NaCl and 0.05% Tween 80.

Details of protein expression, purification, crystallization, data collection, X-ray structure solution and refinement, steady state kinetic measurements and inhibition experiments are listed in **S1 Appendix**.

**Supporting Information**

**S1 Appendix.** Details of protein expression, purification, crystallization, data collection, X-ray structure solution and refinement, steady state kinetic measurements and inhibition experiments.

(DOCX)

**S1 Fig.** Multiple sequence alignments of IMPDHs. (A) Sequence alignment of three *Mtb* IMPDHs: *Mtb*IMPDH1 (guaB1; gi: 15608980), *Mtb*IMPDH2 (guaB2; gi: 15610547) and *Mtb*IMPDH3 (guaB3; gi: 444896966). Secondary structure elements derived from *Mtb*IMPDH2ΔCBS (PDB code 4ZQR) are depicted as arrows (representing β-strands), coils (representing α- and 310-helices), TT (strict β-turns) and TTT (strict α-turns). The location of CBS domain is shown as a green line. The position of catalytic Cys residue is indicated by a yellow rectangle. It is important to note that *Mtb*IMPDH3 (guaB3) does not posses the catalytic Cys residue suggesting that this protein may not be an IMPDH enzyme. (B) Sequence alignment of bacterial and human IMPDHs discussed in this study. The sequences include *Mtb*IMPDH1 (guaB1; gi: 15608980), *Mtb*IMPDH2 (guaB2; gi: 15610547), *B. anthracis* str. Ames (gi: 30253523), *V. cholera* O1 biovar (gi: 15640786), human type I (gi: 217035148), human type II (gi: 66933016) and *C. parvum* (gi: 323510309). *Mtb*IMPDH3 was omitted. Secondary structure elements derived from *Bal*IMPDH (PDB code 3TSB) are depicted as in panel A. The location of CBS domain is shown as a green line. The position of catalytic Cys residue is indicated by a yellow rectangle. Positions of residues involved in binding of the NAD^+ adenine moiety in bacterial (A^E^-subsite) and eukaryotic (A^E^-subsite) enzymes are indicated by purple and black rectangles, respectively. In both panels identical residues are highlighted in red, and similar residues are shown as red letters. The alignment was generated using MultiAlin [54] and ESPript [55] programs.

(TIFF)
S2 Fig. Comparison of the effect of inhibitors on MtbIMPDH and BalMPDH. The line denotes equal values of $K_{i,app}$.

S3 Fig. Comparison of MIC for antitubercular activity and $K_{i,app}$ for inhibition of MtbIMPDH.

S4 Fig. MtbIMPDH2ΔCBS catalyzes the transfer of hydride to the pro-S face of NAD$^+$. NMR spectra of IMPDH reaction mixtures after 2 h incubation of NAD$^+$ with (A) hIMPDH2 (1.3 μM) and IMP; (B) hIMPDH2 (1.3 μM) and [2-$^2$H]-IMP; (C) MtbIMPDH2ΔCBS (1 μM) and IMP; (D) MtbIMPDH2ΔCBS (1 μM) and [2-$^2$H]-IMP. The peaks assigned to protons on C–4 of NADH nicotinamide ring are shown.

S1 Table. Structures of inactive A series amide derivatives. All values are the average of at least two determinations unless otherwise noted. a. Data from [24]. b. Data from [23]. c. Data from [37]. d. Single determination.

S2 Table. Structures of inactive A series triazole derivatives. a. Data from [24]. b. Data from [37]. c. Single determination.

S3 Table. SAR of enzyme inhibition for C series benzimidazole derivatives. n.d. = not determined. a. CplMPDH data from [30]. b. Data from [25]. c. BalMPDH data from [37]. c. Single determination.

S4 Table. Structures of inactive D series phthalazinone derivatives. n.d. = not determined. a. Data from [28]. b. Data from [37]. c. Single determination.

S5 Table. Structures of inactive P compounds. n.d. = not determined. a. Data from [26]. b. Data from [37].

S6 Table. P series: SAR of enzyme inhibition for the isopropyl and urea group. n.d. = not determined. a. Data from [26]. b. Data from [37].

S7 Table. Structures of inactive Q compounds. n.d. = not determined. n.d. = not determined a. Data from [27]. b. Data from [37].

S8 Table. CplMPDH inhibitors with antitubercular activity: comparison of enzyme inhibition. n.d. = not determined. a. Data from [26]. b. Data from [27]. c. Data from [37]. d. Single determination. e. Two determinations.

S9 Table. Inhibition of MtbIMPDH2ΔCBS. * Indicates tight binding conditions. C, competitive inhibition; UC, uncompetitive inhibition, NC, noncompetitive inhibition.
Acknowledgments

The authors wish to thank members of the Structural Biology Center at Argonne National Laboratory for their help with data collection. We thank Liqiang Chen for providing compound MAD1. This work was supported by the National Institute of Health (NIH) and the National Institute of Allergy and Infectious Diseases (NIAID) [contracts HHSN272200700058C and HHSN272201200026C to the Center of Structural Genomics of Infectious Diseases], grant AI093459 (to LH) and the Intramural Research Program of NIAID (HB). The use of Structural Biology Center beamlines was supported by the U.S. Department of Energy, Office of Biological and Environmental Research [contract DE-AC02-06CH11357].

Author Contributions

Performed the experiments: MMG SKG YW KM MZ NM GM HB MG. Analyzed the data: MMG SKG YK CA GC LH AJ. Wrote the paper: MMG YK LH AJ.

References

1. WHO (2014) Global Tuberculosis Report. Geneva: WHO.
2. Mitchison D, Davies G (2012) The chemotherapy of tuberculosis: past, present and future. Int J Tuberc Lung Dis 16: 724–732. doi: 10.5588/ijtld.12.0083 PMID: 22613684
3. Barry CE, Boshoff HI, Dartois V, Dick T, Ehr T, Flynn J, et al. (2009) The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol 7: 845–855. doi: 10.1038/nrmicro2236 PMID: 19855401
4. Wakamoto Y, Dhar N, Chait R, Schneider K, Signorino-Gelo FB, Leibler S, et al. (2013) Dynamic Persistence of Antibiotic-Stressed Mycobacteria. Science 339: 91–95. doi: 10.1126/science.1229858 PMID: 23288538
5. Ginsberg AM, Spigelman M (2007) Challenges in tuberculosis drug research and development. Nat Med 13: 290–294. PMID: 17342142
6. Gandhi NR, Nunn P, Dheda K, Schaaf HS, Zignol M, van Soolingen D, et al. (2010) Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. The Lancet 375: 1830–1843.
7. Cegielski JP (2010) Extensively Drug-Resistant Tuberculosis: "There must be some kind of way out of here". Clin Infect Dis 50: S195–S200. doi: 10.1086/651491 PMID: 20397948
8. Chakraborty S, Gruber T, Barry CE, Boshoff HI, Rhee KY (2013) Para-Aminosalicylic Acid Acts as an Alternative Substrate of Folate Metabolism in Mycobacterium tuberculosis. Science 339: 88–91. doi: 10.1126/science.1228980 PMID: 23118010
9. Andries K, Verhasselt P, Guillemont J, Göhlmann HWH, Neefs J-M, Winkler H, et al. (2005) A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis. Science 307: 223–227. PMID: 1559164
10. Hedstrom L, Liechti G, Goldberg JB, Gollapalli DR (2011) The Antibiotic Potential of Prokaryotic IMP Dehydrogenase Inhibitors. Curr Med Chem 18: 1909–1918. PMID: 21517780
11. Warner DF, Evans JC, Mizrahi V (2014) Nucleotide Metabolism and DNA Replication. Microbiology Spectrum 2. doi: 10.1128/microbiolspec.MGM2-0001-2013 PMID: 26104350
12. Zhang Y, Morar M, Ealick SE (2008) Structural Biology of the Purine Biosynthetic Pathway. Cellular and molecular life sciences: CMLS 65: 3680–3724. doi: 10.1007/s00018-008-8295-8 PMID: 18712276
13. Cole ST, Broomh R, Parkhill J, Garnier T, Churcher C, Harris D, et al. (1998) Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393: 537–544. PMID: 9634293
14. Usha V, Gurcha SS, Lovering AL, Lloyd AJ, Papaemmanouil A, Reynolds RC, et al. (2011) Identifica- tion of novel diphenyl urea inhibitors of M-GuaB2 active against Mycobacterium tuberculosis. Microbiology 157: 290–299. doi: 10.1099/mic.0.042549-0 PMID: 21081761
15. Sassetti CM, Boyd DH, Rubin EJ (2003) Genes required for mycobacterial growth defined by high density mutagenesis. Mol Microbiol 48: 77–84. PMID: 12657046
16. Chen L, Wilson DJ, Xu Y, Aldrich CC, Felczak K, Sham YY, et al. (2010) Triazole-Linked Inhibitors of Inosine Monophosphate Dehydrogenase from Human and Mycobacterium tuberculosis. J Med Chem 53: 4768–4778. doi: 10.1021/jm100424m PMID: 20491506
17. Usha V, Hobrath JV, Gurcha SS, Reynolds RC, Besra GS (2012) Identification of Novel Mt-Guab2 Inhibitor Series Active against *M. tuberculosis*. PLoS ONE 7: e33886 (33881–33812). doi: 10.1371/journal.pone.0033886 PMID: 22479467

18. Hedstrom L (2009) IMP Dehydrogenase: Structure, Mechanism, and Inhibition. Chem Rev 109: 2903–2928. doi: 10.1021/cr900021w PMID: 19480389

19. Chen L, Pankiewicz Krzysztof W (2007) Recent developments of IMP dehydrogenase inhibitors for the treatment of cancer. Curr Opin Drug Discovery Dev 10: 403–412.

20. Colby TD, Vanderveen K, Strickler MD, Markham GD, Goldstein BM (1999) Crystal structure of human type II inosine monophosphate dehydrogenase: implications for ligand binding and drug design. Proc Natl Acad Sci U S A 96: 3531–3536. PMID: 10097070

21. Makowska-Gryszka M, Kim Y, Maitsaeva N, Osipiuk J, Gu M, Zhang M, et al. (2015) A novel cofactor binding mode in bacterial IMP dehydrogenases explains inhibitor selectivity. J Biol Chem 290: 5893–5911. doi: 10.1074/jbc.M114.619767 PMID: 25572472

22. Umejiego NN, Gollapalli D, Sharling L, Volftsun A, Lu J, Benjamin NN, et al. (2008) Targeting a Prokaryotic Protein in a Eukaryotic Pathogen: Identification of Lead Compounds against Cryptosporidiosis. Chem Biol 15: 70–77. doi: 10.1016/j.chembiol.2007.12.010 PMID: 18215774

23. Sharling L, Liu X, Gollapalli DR, Maurya SK, Hedstrom L, Striepen L (2010) A Screening Pipeline for Antiparasitic Agents Targeting Cryptosporidium Inosine Monophosphate Dehydrogenase. PLoS Negl Trop Dis 4: e794 (791–712). doi: 10.1371/journal.pntd.0000794 PMID: 20706578

24. Maurya SK, Gollapalli DR, Kirubakaran S, Zhang M, Johnson CR, Benjamin NN, et al. (2009) Triazole Inhibitors of *Cryptosporidium parvum* Inosine 5'-Monophosphate Dehydrogenase. J Med Chem 52: 4623–4630. doi: 10.1021/jm900410u PMID: 19624136

25. Kirubakaran S, Gorla SK, Sharling L, Zhang M, Liu X, Ray SS, et al. (2012) Structure-activity relationship study of selective benzimidazole-based inhibitors of *Cryptosporidium parvum* IMPDH. Bioorg Med Chem Lett 22: 1985–1988. doi: 10.1016/j.bmcl.2012.01.029 PMID: 22310229

26. Gorla SK, Kavitha M, Zhang M, Liu X, Sharling L, Gollapalli DR, et al. (2012) Selective and Potent Urea Inhibitors of *Cryptosporidium parvum* Inosine 5'-Monophosphate Dehydrogenase. J Med Chem 55: 7759–7771. doi: 10.1021/jm3007917 PMID: 22950983

27. Gorla SK, Kavitha M, Zhang M, Chin JEW, Liu X, Striepen B, et al. (2013) Optimization of Benzoxazole-Based Inhibitors of *Cryptosporidium parvum* Inosine 5'-Monophosphate Dehydrogenase. J Med Chem 56: 4028–4043. doi: 10.1021/jm400241j PMID: 23668331

28. Johnson CR, Gorla SK, Kavitha M, Zhang M, Liu X, Striepen B, et al. (2013) Phthalalazine inhibitors of inosine–5'-monophosphate dehydrogenase from *Cryptosporidium parvum*. J Med Chem 56: 1004–1007. doi: 10.1021/jm400241j PMID: 23324406

29. Sun Z, Khan J, Makowska-Gryszka M, Zhang M, Cho JH, Suebsuwong C, et al. (2014) Synthesis, in Vitro Evaluation and Cocrystal Structure of 4-Oxo-[1]benzopyran-4(3-c)-pyrazole Cryptosporidium parvum Inosine 5'-Monophosphosphate Dehydrogenase (CpIMPDH) Inhibitors. J Med Chem 57: 10544–10550. doi: 10.1021/jm5015272 PMID: 25474504

30. MacPherson IS, Kirubakaran S, Gorla SK, Riera TV, D'Aquino JA, Zhang M, et al. (2010) The Structural Basis of *Cryptosporidium*-Specific IMP Dehydrogenase Inhibitor Selectivity. J Am Chem Soc 132: 1230–1231. doi: 10.1021/ja909947a PMID: 20052976

31. Gollapalli DR, MacPherson IS, Liecht G, Gorla SK, Goldberg JB, Hedstrom L (2010) Structural Determinants of Inhibitor Selectivity in Prokaryotic IMP Dehydrogenases. Chem Biol 17: 1084–1091. doi: 10.1016/j.chembiol.2010.07.014 PMID: 21035731

32. Makowska-Gryszka M, Kim Y, Wu R, Wilton R, Gollapalli DR, Wang KK, et al. (2012) *Bacillus anthracis* Inosine 5'-Monophosphate Dehydrogenase in Action: The First Bacterial Series of Structures of Phosphate Ion-, Substrate-, and Product-Bound Complexes. Biochemistry 51: 6148–6163. PMID: 22789666

33. Carr SF, Papp E, Wu J, Natsumeda Y (1993) Characterization of Human Type I and Type II IMP Dehydrogenase. J Biol Chem 268: 27286–27290. PMID: 7903306

34. Hager PW, Collart FR, Huberman E, Mitchell BS (1995) Recombinant Human Inosine Monophosphate Dehydrogenase Type I and Type II Proteins. Biochem Pharmacol 49: 1323–1329. PMID: 7763314

35. Mortimer SE, Hedstrom L (2005) Autosomal dominant retinitis pigmentosa mutations in inosine 5'-monophosphate dehydrogenase type I disrupt nucleic acid binding. Biochem J 390: 41–47. PMID: 15882147

36. Wang W, Hedstrom L (1997) Kinetic Mechanism of Human Inosine 5'-Monophosphate Dehydrogenase Type II: Random Addition of Substrates and Ordered Release of Products. Biochemistry 36: 8479–8483. PMID: 9214292
37. Mandapati K, Gorla SK, House AL, McKenney ES, Rao SN, Gollapalli DR, et al. (2014) Repurposing Cryptosporidium inosine 5’-monophosphate dehydrogenase inhibitors as potential antibacterial agents. ACS Med Chem Lett 5: 846–850. doi: 10.1021/ml500203p PMID: 25147601

38. Gorla SK, McNair NN, Yang G, Gao S, Hu M, Jala VR, et al. (2014) Validation of IMP dehydrogenase inhibitors in a mouse model of cryptosporidiosis. Antimicrob Agents Chemother 58: 1603–1614. doi: 10.1128/AAC.02075-13 PMID: 25147601

39. Rejman D, Olesiak M, Chen L, Patterson SE, Wilson D, Jayaram HN, et al. (2006) Novel Methylene-phosphophosphonate Analogues of Mycophenolic Adenine Dinucleotide. Inhibition of Inosine Monophosphate Dehydrogenase. J Med Chem 49: 5018–5022. PMID: 16884314

40. Lesiak K, Watanabe KA, Majumdar A, Powell J, Seidman M, Vanderveen K, et al. (1998) Synthesis of a Methylenebis(phosphonate) Analogue of Mycophenolic Adenine Dinucleotide: A Glucuronidation-Resistant MAD Analogue of NAD. J Med Chem 41: 618–622. PMID: 9484510

41. Sintchak MD, Fleming MA, Futer O, Raybuck SA, Chambers SP, Caron PR, et al. (1996) Structure and mechanism of inosine monophosphate dehydrogenase in complex with the immunosuppressant mycophenolic acid. Cell 85: 921–930. PMID: 8681386

42. Prosise GL, Wu JZ, Luecke H (2002) Crystal structure of Trichomonas foetus inosine monophosphate dehydrogenase in complex with the inhibitor ribavirin monophosphate reveals a catalysis-dependent ion-binding site. J Biol Chem 277: 50654–50659. PMID: 12235158

43. Kuppuraj G, Sargsyan K, Hua Y-H, Merrill AR, Lim C (2011) Linking Distinct Conformations of Nicotinamide Adenine Dinucleotide with Protein Fold/Function. J Phys Chem B 115: 7932–7939. doi: 10.1021/jp1118663 PMID: 21612228

44. Prosise GL, Luecke H (2003) Crystal structures of Trichomonas foetus inosine monophosphate dehydrogenase in complex with substrate, cofactor and analogs: a structural basis for the random-in ordered-out kinetic mechanism. J Mol Biol 326: 517–527. PMID: 12559919

45. Cooney D, Hamel E, Cohen M, Kang GJ, Dalal M, Marquez V (1987) A simple method for the rapid determination of the stereospecificity of NAD-dependent dehydrogenases applied to mammalian IMP dehydrogenase and bacterial NADH peroxidase. Biochim Biophys Acta, Protein Struct Mol Enzymol 916: 89–93.

46. Xiang B, Markham GD (1997) Probing the mechanism of inosine monophosphate dehydrogenase with kinetic isotope effects and NMR determination of the hydride transfer stereospecificity. Arch Biochem Biophys 348: 378–382. PMID: 9434751

47. Voth AR, Khuu P, Oishi K, Ho PS (2009) Halogen bonds as orthogonal molecular interactions to hydrogen bonds. Nat Chem 1: 74–79. doi: 10.1038/nchem.112 PMID: 21378804

48. Bissantz C, Kuhn B, Stahl M (2010) A Medicinal Chemist’s Guide to Molecular Interactions. J Med Chem 53: 5061–5084. doi: 10.1021/jm100112j PMID: 20345171

49. Cotton NPJ, White SA, Peake SJ, McSweeney S, Jackson JB (2001) The Crystal Structure of an Asymmetric Complex of the Two Nucleotide Binding Components of Proton-Translocating Transhydrogenase. Structure 9: 165–176. PMID: 11250201

50. Thoden JB, Frey PA, Holden HM (1996) Crystal Structures of the Oxidized and Reduced Forms of UDP-galactose 4-Epimerase Isolated from Escherichia coli. Biochemistry 35: 2557–2566. PMID: 8611559

51. Geiser M, Cébe R, Drewello D, Schmitz R (2001) Integration of PCR Fragments at any Specific Site within Cloning Vectors without the Use of Restriction Enzymes and DNA Ligase Biotechniques 31: 88–92. PMID: 11464525

52. Kim Y, Babnigg G, Jedrzejcak R, Eschenfeldt WH, Li H, Malteva N, et al. (2011) High-throughput protein purification and quality assessment for crystallization. Methods 55: 12–28. doi: 10.1016/j.ymeth.2011.07.010 PMID: 21907284

53. Duckworth BP, Wilson DJ, Nelson KM, Boshoff HL, Barry CE, Aldrich CC (2012) Development of a Selective Activity-Based Probe for Adenylation Enzymes: Profiling MbtA Involved in Siderophore Biosynthesis from Mycobacterium tuberculosis. ACS Chem Biol 7: 1653–1658. doi: 10.1021/cb300112x PMID: 22796950

54. Corpet F (1988) Multiple sequence alignment with hierarchical clustering. Nucleic Acids Res 16: 10881–10890. PMID: 2849754

55. Robert X, Gouet P (2014) Deciphering key features in protein structures with the new ENDscript server. Nucleic Acids Res 42: W320–W324. doi: 10.1093/nar/gku1038 PMID: 24753421